VisMederi and KingMylab have announced the signing of a strategic collaboration agreement aimed at strengthening testing and analytical services for vaccine and biologics clinical trials.
The partnership combines KingMylab’s expertise in central laboratory services for clinical research with VisMederi’s extensive experience in vaccine evaluation, bioanalytical assay development, and the generation of scientific data supporting clinical development programs.
As the global healthcare community continues to face emerging infectious disease threats and increasing pressure to accelerate the development of innovative vaccines, access to reliable, standardized, and internationally compliant testing services has become more critical than ever.
The partnership will focus particularly on supporting Multi-Regional Clinical Trials (MRCTs) by implementing harmonized processes and comparable testing methodologies across participating study sites worldwide. This approach will ensure high-quality, consistent, and globally acceptable data, facilitating international regulatory pathways and accelerating the development of innovative vaccines and biologics.
This partnership marks an important milestone in VisMederi’s international growth strategy. By combining VisMederi’s scientific expertise with KingMylab’s strong operational presence in Asia, we will be able to provide our partners with increasingly integrated, high-value solutions for the global development of vaccines.
